Rituximab treatment stabilizes disability in SPMS patients: Analysis
Treatment with rituximab, a CD20 inhibitor used off-label for multiple sclerosis (MS) patients, can stabilize disability progression and reduce disease activity in people with secondary progressive MS (SPMS), according to a review of several published studies. These benefits were reported over a mean follow-up of two years, and…